Free tool
FAERS Monitor: Haldol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018701 or its brand name (Haldol, Haloperidol Decanoate). Reports on generic versions are filed under their own applications.
Reports
1,743
Serious
1,546
89% of reports
Hospitalization
800
Death reported
153
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- weight increased241
- drug ineffective168
- extrapyramidal disorder147
- off label use134
- akathisia127
- drug interaction116
- suicide attempt107
- leukopenia97
- toxicity to various agents97
- neuroleptic malignant syndrome96
- product use in unapproved indication84
- treatment noncompliance73
- tremor73
- therapeutic product effect incomplete68
- euphoric mood67
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 30 |
| 2005 | 34 |
| 2006 | 42 |
| 2007 | 190 |
| 2008 | 19 |
| 2009 | 65 |
| 2010 | 31 |
| 2011 | 26 |
| 2012 | 41 |
| 2013 | 50 |
| 2014 | 59 |
| 2015 | 76 |
| 2016 | 49 |
| 2017 | 64 |
| 2018 | 45 |
| 2019 | 87 |
| 2020 | 77 |
| 2021 | 101 |
| 2022 | 134 |
| 2023 | 165 |
| 2024 | 131 |
| 2025 | 146 |
| 2026 | 81 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,416 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| akathisiaSignal | 127 | 113.4 | 95.8 | 13,910 |
| neuroleptic malignant syndromeSignal | 96 | 98.5 | 81.0 | 9,095 |
| euphoric moodSignal | 67 | 79.4 | 62.8 | 5,080 |
| extrapyramidal disorderSignal | 147 | 71.9 | 61.5 | 10,151 |
| leukopeniaSignal | 97 | 23.4 | 19.3 | 2,063 |
| suicide attemptSignal | 107 | 21.3 | 17.7 | 2,055 |
| treatment noncomplianceSignal | 73 | 16.1 | 12.9 | 1,022 |
| weight increasedSignal | 241 | 13.0 | 11.6 | 2,683 |
| therapeutic product effect incompleteSignal | 68 | 11.5 | 9.1 | 646 |
| drug interactionSignal | 116 | 8.8 | 7.4 | 803 |
| toxicity to various agentsSignal | 97 | 6.9 | 5.7 | 491 |
| tremorSignal | 73 | 5.3 | 4.2 | 253 |
| product use in unapproved indicationSignal | 84 | 4.1 | 3.3 | 195 |
| off label use | 134 | 1.8 | 1.6 | 53 |
| drug ineffective | 168 | 1.5 | 1.3 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.